Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe

Baker, Dewleen G.; Bertram, Tobias Moeller; Patel, Piyush M.; Barkauskas, Donald A.; Clopton, Paul; Patel, Sejal; Geracioti, Thomas D.; Haji, Uzair; O’Connor, Daniel T.; Nievergelt, Caroline M.; Hauger, Richard L.

doi:10.1016/j.psyneuen.2013.04.020

Cited by 26 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our analysis, the source of NPY (CSF vs. plasma) was not associated with changes in SMDs (effect size, see Supporting Information 3, Table ). This suggests that changes in the NPY levels in plasma or CSF are likely proportional, in agreement with Baker and colleagues (). It is simply that in our data CSF NPY levels in MDD did not achieve statistical significance.…”

Section: Discussionsupporting

confidence: 90%

“…Previous studies have reported that NPY levels in CSF are approximately two to threefold higher than in plasma (Baker et al, 2013;Dötsch et al, 1997). The ratio is constant over 24 hr, and is independent of changes in personal or physiological parameters (Baker et al, 2013).…”

Section: Discussionmentioning

confidence: 84%

“…Previous studies have reported that NPY levels in CSF are approximately two to threefold higher than in plasma (Baker et al, ; Dötsch et al, ). The ratio is constant over 24 hr, and is independent of changes in personal or physiological parameters (Baker et al, ). In our analysis, the source of NPY (CSF vs. plasma) was not associated with changes in SMDs (effect size, see Supporting Information 3, Table ).…”

Section: Discussionmentioning

confidence: 93%

See 2 more Smart Citations

Neuropeptide Y in PTSD, MDD, and chronic stress: A systematic review and meta‐analysis

Tural

Iosifescu

2020

J of Neuroscience Research

View full text Add to dashboard Cite

Previous studies have suggested that neuropeptide Y (NPY) levels may be altered in patients with major depressive disorder (MDD), post‐traumatic stress disorder (PTSD) and chronic stress. We investigated, through systematic review and meta‐analysis, whether the mean levels of NPY are significantly different in patients with MDD, PTSD or chronic stress, compared to controls. The main outcome was the pooled standardized mean difference (SMD) with 95% confidence intervals between cases and controls, using the random‐effects model. Heterogeneity and publication bias were evaluated. Thirty‐five studies met eligibility criteria. Meta‐regression determined that medication and sex could explain 27% of the between‐study variance. Females and participants currently prescribed psychotropic medications had significantly higher levels of NPY. NPY levels were significantly lower in plasma and cerebrospinal fluid (CSF) in PTSD patients versus controls. Patients with MDD had significantly lower levels of NPY in plasma compared to controls, but not in the CSF. The magnitudes of the decrease in plasma NPY levels were not significantly different between PTSD and MDD. However, chronic stress patients had significantly higher plasma NPY levels compared to controls, PTSD or MDD. Our findings may imply a shared role of NPY in trauma and depression: nevertheless, it is not clear that the association is specific to these disorders. Psychotropic medications may help restore NPY levels. Further controlled studies are needed to better delineate the contribution of confounding variables such as type of depression, body mass index, appetite or sleep architecture.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Neuropeptide Y in PTSD, MDD, and chronic stress: A systematic review and meta‐analysis

Tural

Iosifescu

2020

J of Neuroscience Research

View full text Add to dashboard Cite

show abstract

“…In the SVF fraction of adipose tissue from mice, secreted NPY was reported to be in the picomolar range, consistent with physiological concentrations in humans [29]. Recent studies showed that the concentration of cerebrospinal fluid (CSF) NPY (cNPY; 792.1 pg/mL) was 3 fold greater than plasma NPY (pNPY; 220.0 pg/mL) in humans [81]. Therefore, whether hypothalamus-derived NPY can enter the blood stream is critical in understanding the regulation of food intake and fat deposition.…”

Section: Introductionmentioning

confidence: 86%

Hypothalamus-adipose tissue crosstalk: neuropeptide Y and the regulation of energy metabolism

2014

View full text Add to dashboard Cite

Neuropeptide Y (NPY) is an orexigenic neuropeptide that plays a role in regulating adiposity by promoting energy storage in white adipose tissue and inhibiting brown adipose tissue activation in mammals. This review describes mechanisms underlying NPY’s effects on adipose tissue energy metabolism, with an emphasis on cellular proliferation, adipogenesis, lipid deposition, and lipolysis in white adipose tissue, and brown fat activation and thermogenesis. In general, NPY promotes adipocyte differentiation and lipid accumulation, leading to energy storage in adipose tissue, with effects mediated mainly through NPY receptor sub-types 1 and 2. This review highlights hypothalamus-sympathetic nervous system-adipose tissue innervation and adipose tissue-hypothalamus feedback loops as pathways underlying these effects. Potential sources of NPY that mediate adipose effects include the bloodstream, sympathetic nerve terminals that innervate the adipose tissue, as well as adipose tissue-derived cells. Understanding the role of central vs. peripherally-derived NPY in whole-body energy balance could shed light on mechanisms underlying the pathogenesis of obesity. This information may provide some insight into searching for alternative therapeutic strategies for the treatment of obesity and associated diseases.

show abstract

“…First, overweight or obesity accompanied with increased levels of NPY in type 2 diabetes might mask the true relationship between DPP4, depression risk and NPY. Second, peripheral NPY concentrations have not been proven to reflect altered NPY levels in the CNS [10]. Third, there are methodological differences, medication use and the heterogeneous nature of depression.…”

Section: Figmentioning

confidence: 99%

Plasma Dipeptidyl Peptidase-4 Activity, a Novel Biomarker or Even a Possible Therapeutic Target for Depression in Type 2 Diabetic Patients: Results from a Cross-Sectional Study in China

Zheng

Qin²,

Chen³

et al. 2017

Psychother Psychosom

View full text Add to dashboard Cite

Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe

Cited by 26 publications

References 12 publications

Neuropeptide Y in PTSD, MDD, and chronic stress: A systematic review and meta‐analysis

Neuropeptide Y in PTSD, MDD, and chronic stress: A systematic review and meta‐analysis

Hypothalamus-adipose tissue crosstalk: neuropeptide Y and the regulation of energy metabolism

Plasma Dipeptidyl Peptidase-4 Activity, a Novel Biomarker or Even a Possible Therapeutic Target for Depression in Type 2 Diabetic Patients: Results from a Cross-Sectional Study in China

Contact Info

Product

Resources

About